Page 78 - Priority Review News Today

- Approval based on the DESTINY-Breast04 results which showed Enhertu reduced risk of disease progression or death by 50 per cent and increased overall survival

KENILWORTH (NJ) (dpa-AFX) - Seagen Inc. (SGEN) said Thursday that the U.S. Food and Drug Administration has granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for

The FDA has accepted for Priority Review the New Drug Application for OPNT003 (nasal nalmefene) for the treatment of opioid overdose.

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Data Bridge Market Research completed a qualitative study titled "Ophthalmology Market" with 100+ market data tables, pie charts, graphs, and figures spread

Data Bridge Market Research analyses that the market is growing with a CAGR of 6.4% in the forecast period of 2023 to 2030 and is expected to reach USD...

New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZenecas Tezspire has received a positive opinion from the... | January 13, 2023

Tezspire is the first biologic approved in Europe for severe asthma with no phenotype or biomarker limitation, says AstraZeneca EVP.

The FDA has accepted for Priority Review the BLA for rozanolixizumab for the treatment of adults with generalized myasthenia gravis.

Italian biopharma Chiesi Farmaceutici SpA announced Sunday it was acquiring rare disease-focused Amryt Pharma in a deal that could reach up to $1.48 billion in value.